| Description | Dilpacimab (ABT165), a potent dual-variable domain immunoglobulin, targets both the delta-like ligand 4 (DLL4) and VEGF pathways. It has potential applications in cancer research [1]. |
| molecular weight | N/A |
| CAS | 1791420-09-1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 years |